Bori Segura Gerardo, Hernández Cruz Blanca, Gobbo Milena, Lanas Arbeloa Angel, Salazar Páramo Mario, Terán Estrada Leobardo, Díaz González José Federico, Espinosa Morales Rolando, Galván Villegas Federico, García Rodríguez Luis Alberto, Alvaro-Gracia Álvaro José María, Avila Armengol Hilario, Carmona Loreto, Rivera Redondo Javier, Ventura Ríos Lucio
Servicio de Reumatología, Hospital General de Zona 32 (Villa Coapa), Instituto Mexicano del Seguro Social, México DF, México.
Reumatol Clin. 2009 Feb;5(1):3-12. doi: 10.1016/S1699-258X(09)70197-4. Epub 2009 Feb 28.
To develop guidelines for the appropriate use of NSAIDs in rheumatology.
We used a methodology modified from the one developed by RAND/UCLA. Two groups of panellists were selected, one by the CMR and another by the SER. Recommendations were proposed from nominal groups and the agreement to them was tested among rheumatologists from both societies by a tworound Delphi survey. The analysis of the second Delphi round supported the generation of the final set of recommendations and the assignment of a level of agreement to each of them. Systematic reviews of five recommendations in which the agreement was low or was divided were also carried out.
Here we present recommendations for the safe use of NSAIDs in rheumatic diseases, based on the best available evidence, expert opinion, the agreement among rheumatologists, and literature review. The trend is to reduce the frequency, duration and dose of NSAIDs in favour of non-pharmacological measures, analgesic drugs or disease modifying drugs. In addition, the recommendations help to identify profiles for increased toxicity, with an emphasis on gastrointestinal and cardiovascular risks. The recommendations deal with the course of action and monitoring in different risk groups and in patients using antiplatelet or anticoagulant drugs. The overall level of agreement is high.
The NSAIDs are safe and effective drugs for the treatment of rheumatic diseases. However, it is necessary to individualize its use according to their risk profile.
制定风湿病领域非甾体抗炎药合理使用的指南。
我们采用了一种对由兰德公司/加州大学洛杉矶分校开发的方法进行修改后的方法。挑选了两组专家小组成员,一组由CMR挑选,另一组由SER挑选。通过名义小组提出建议,并通过两轮德尔菲调查在两个学会的风湿病学家中测试他们对这些建议的认同度。对第二轮德尔菲调查的分析支持了最终建议集的生成以及为每条建议确定认同度水平。还对五条认同度低或存在分歧的建议进行了系统评价。
在此,我们基于现有最佳证据、专家意见、风湿病学家之间的共识以及文献综述,提出了在风湿性疾病中安全使用非甾体抗炎药的建议。趋势是减少非甾体抗炎药的使用频率、持续时间和剂量,转而采用非药物措施、镇痛药或改善病情的药物。此外,这些建议有助于识别毒性增加的特征,重点关注胃肠道和心血管风险。这些建议涉及不同风险组以及使用抗血小板或抗凝药物的患者的行动过程和监测。总体认同度较高。
非甾体抗炎药是治疗风湿性疾病的安全有效药物。然而,有必要根据其风险特征对其使用进行个体化。